Gem Aromatics Limited has informed the Exchange regarding a press release dated May 21, 2026, titled "Financial Results of the Company for the period ended on March 31, 2026".
GEMAROMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Gem Aromatics reported standalone FY26 revenue of Rs 370.9 Cr, down 25% from Rs 497 Cr in FY25. Consolidated PAT crashed to just Rs 1.4 Cr for FY26 versus Rs 53.4 Cr in FY25, a 97% decline. The sharp profit drop is attributed to higher depreciation from the Rs 260 Cr Dahej facility capex now being capitalized. However, Q4FY26 showed sequential recovery with revenue of Rs 110.4 Cr (consolidated) and PAT of Rs 1 Cr, up from a loss of Rs 5 Cr in Q3. Gross margins improved to 30.5% in Q4 from 25.2% in Q3. New products GEM Cool 5 and Safranal commenced commercial production in February 2026. The company flagged geopolitical issues impacting phenol raw material prices, affecting phenol derivatives production timelines.
The stock faces pressure from severely depressed FY26 profits, though Q4 sequential recovery and improving margins offer some relief. The large Dahej capex weighing on near-term earnings should normalize with higher utilization, but geopolitical raw material risks add uncertainty to the phenol derivatives business outlook.